Journal of Cardiovascular Development and Disease
Colchicine Use Is Associated with Shorter ICU Stay and Lower FFP Transfusion Requirements After CABG
By Mehmet Burak Gülcan, Mehmet Ali Kayğın, Aycan Mutlu Yaganoglu and 4 others.
Abstract
Background
Colchicine has demonstrated anti-inflammatory and cardiovascular benefits in patients with coronary heart disease. However, evidence regarding its effects on postoperative inflammation and early clinical outcomes following coronary artery bypass grafting (CABG) remains limited.
Objective
We aimed to evaluate the association between perioperative low-dose colchicine use and postoperative clinical outcomes, transfusion requirements, complications, and inflammatory markers in patients undergoing elective on-pump CABG.
Methods
This retrospective study included 151 patients who underwent elective on-pump CABG: 81 received colchicine (0.5 mg once daily for 3 days preoperatively and 10 days postoperatively) and 70 did not receive colchicine in the past period. The primary clinical outcomes included ICU and total hospital length of stay, erythrocyte and fresh frozen plasma (FFP) transfusion requirements, wound complication, and surgical revision. Postoperative day 5 laboratory parameters included C-reactive protein, white blood cell (WBC) count, systemic immune-inflammation index (SII), and albumin. Between-group comparisons were performed using Student’s or Welch’s t tests and Pearson’s chi-square or Fisher’s exact tests, as appropriate.